Abbvie Inc (ABBV) Stock Price, Quote & News

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 847 932 7900

Website: www.abbvie.com

Address:

1 North Waukegan Road, North Chicago, United States

clan Jun. 1 at 12:15 PM

$GSK Great news for diabetic kiddos!!! FDA APPROVED - - - AFREZZA For the good of all MannKind! T1Ds and Type 2s are NOW ready for the future! Inhalable mealtime insulin! Wow! 😲😃 $ABBV $JNJ $MRK

0 · Reply

55X_ROI_Q1_2026 Jun. 1 at 5:37 AM

$SLS $ABBV

1 · Reply

maikl_211 Jun. 1 at 4:29 AM

$PLTR $COST $NFLX $BAC $ABBV

0 · Reply

Loudermilk64 Jun. 1 at 4:23 AM

$ABBV dead money.

0 · Reply

55X_ROI_Q1_2026 Jun. 1 at 3:26 AM

$SLS $ABBV VIALE-M Failed a CR1 Maintenance Trial - 7 different Dosing Regimes - Aza+ven Is not Effective for Remission Maintenance - Aza+VEN is not effective in the REGAL Phase 3 CR2 Maintenance Trial. https://clinicaltrials.gov/study/NCT04102020?term=viale-M&viewType=Card&rank=1&tab=study -- the Results are Linked... Viale-T Post Transplant Trial Also FAILED ... It is GPS ... Doing what its done in all Previous Trials, prevent relapse and extend survival.

0 · Reply

55X_ROI_Q1_2026 Jun. 1 at 3:14 AM

$SLS Does everyone Realize Aza+VEN - BAT - Best Available Treatment for CONTROL ARM Patients - Recently FAILED 3 Large Phase 3 Trials - Including the VIALE-M First Remission CR1 Maintenance Trial?? and GPs MOS in 2 Phase 2 Trials for REMISSION Maintenance were 2x and 4x Standard Care. - 'tis not complicated. - IDMC Unblinded Actual Phase 3 MOS and IR Data from the Interim VERY RARE TO HAVE Survival and Immune Response Data from an Ongoing P3. - pro tip for the Passersby, its been about 3 weeks since the 78th announcement - event rate 1x / 3weeks, so imminent it is - and the 60th Unblinded IDCM MOS and IR data told most Gps is Golden. 72nd Event Announced / Price Launched 78th Event Announced / Again Share Price Launched 80th EVENT PR will Launch the Share Price - the TIP, you will Know all you Need to Know about Gps Success when you See the Smart Money Buying the Share Price Up to $18 / $20 $3B/ $4B -Buy and HoDl. 10x to 27X ROI on the Table -- THIS MONTH. $ABBV https://www.cancernetwork.com/view/galinpepimut-s-completes-phase-3-regal-interim-analysis-in-aml

0 · Reply

TruthBroker2 May. 31 at 3:22 PM

$ABBV $ISRG $PLSE $SMMT.

0 · Reply

55X_ROI_Q1_2026 May. 31 at 3:32 AM

$SLS $ABBV 'No Patients Exhibiting Durable CD4 Response Relapsed' -- Check the Charts where "GPS Dosing ENDS" Investment Opportunity of a Lifetime --- $50 Per Share is only $9.5B Mcap --- $100 Per Share $19B - All Known Data Points to GPS Phase 3 MOS > 30.5 months, and not yet met vs GPS P2 MOS of 21 months - Stat Sig .02 Pvalue ie 98% likely GPS Phase 3 Patient - Infinite Dosing to Relapse - is the Reason we are Seeing Miraculous Survival in the REGAL TRIAL. AND also the Reason this $1.7B Equity will be a $17B Equity the Instant the Entire Market Sees the Registrational Phase 3 Results. Be Holding the moment the 80th Event PR is announce - its Rings the BIG Boy Dinner Bell. Bank on it - Vangaurd Black Rock and the like will be Sacking up 100K Blocks (saw 250K yesterday) at $50 Per share . . > watch $9 and change will be $90 and Climbing.

0 · Reply

amessagefromtheodd May. 30 at 11:24 AM

$SLS When / if SELLAS delivers strong AML data, the market will have its proof. At that point, the debate shifts from “does it work?” to “how big can the AML opportunity get, and who wants to own it?” $MRK $ABBV $PFE $RHHBY

1 · Reply

clan May. 29 at 9:22 PM

$MNKD ⚠️ FDA APPROVAL ⚠️ Inhalable mealtime insulin for pediatrics! Wow! 😲 Good for kids, mankind, and Mannkind ! ... and Cipla too ! $CIPLA.NSE 🇮🇳 $GSK $ABBV

0 · Reply

AbbVie announces EC authorizes expanded label for Venclyxto

May 29, 2026, 8:00 AM EDT - 3 days ago

AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia

May 27, 2026, 6:18 PM EDT - 4 days ago

U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options

May 27, 2026, 3:33 PM EDT - 4 days ago

US FDA approves AbbVie's rare blood cancer drug

2026-05-27T19:25:11.000Z - 4 days ago

FDA approves AbbVie’s Decnupaz for blastic plasmacytoid dendritic cell neoplasm

2026-05-22T12:12:15.000Z - 10 days ago

AbbVie reports positive CHMP opinion for Maviret

May 22, 2026, 8:00 AM EDT - 10 days ago

AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection

May 21, 2026, 6:46 PM EDT - 10 days ago

AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline

2026-05-21T20:19:37.000Z - 10 days ago

AbbVie’s Allergan Aesthetics receives positive CHMP opinion for Boey

May 21, 2026, 4:10 PM EDT - 10 days ago

Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults

2026-05-15T12:51:42.000Z - 16 days ago

AbbVie price target lowered to $235 from $236 at Evercore ISI

2026-05-14T20:15:24.000Z - 17 days ago

3 ‘Strong Buy’ Dividend Aristocrat Stocks with 100%+ Payout Ratios, 5/14/26

ABT NEE

2026-05-14T11:07:12.000Z - 18 days ago

AbbVie price target raised to $298 from $294 at Piper Sandler

May 13, 2026, 2:20 PM EDT - 18 days ago

AbbVie Transcript: Bank of America Global Healthcare Conference 2026

May 8, 2026, 10:00 AM EDT - 23 days ago

AbbVie Transcript: AGM 2026

May 6, 2026, 8:00 AM EDT - 26 days ago

AbbVie to Present at the Bank of America Securities Healthcare Conference

2026-05-05T12:32:52.000Z - 26 days ago

AbbVie presented new data across its gastroenterology portfolio at the 2026 DDW

May 5, 2026, 8:05 AM EDT - 27 days ago

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

IBD

2026-05-04T12:13:35.000Z - 4 weeks ago

AbbVie price target raised to $236 from $232 at Evercore ISI

May 1, 2026, 3:05 PM EDT - 4 weeks ago

AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried

May 1, 2026, 10:03 AM EDT - 4 weeks ago

Big Pharma M&A set for mega year as patent expiries drive deal urgency

BMY GILD GSK LLY

Apr 30, 2026, 3:00 PM EDT - 4 weeks ago

AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

2026-04-30T18:00:46.000Z - 4 weeks ago

AbbVie price target raised to $278 from $270 at Morgan Stanley

2026-04-30T13:31:03.000Z - 4 weeks ago

AbbVie price target raised to $265 from $262 at Canaccord

Apr 30, 2026, 9:00 AM EDT - 4 weeks ago

Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month

2026-04-30T10:15:57.000Z - 4 weeks ago

AbbVie upgraded to Buy at BofA on durable growth

2026-04-30T10:14:18.000Z - 4 weeks ago

AbbVie upgraded to Buy from Neutral at BofA

2026-04-29T16:41:09.000Z - 4 weeks ago

AbbVie raises FY26 revenue view to about $67.3B from about $67B

Apr 29, 2026, 9:00 AM EDT - 4 weeks ago

AbbVie Earnings Call Transcript: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 4 weeks ago

AbbVie Earnings release: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 4 weeks ago

AbbVie Quarterly report: Q1 2026

Apr 29, 2026, 8:32 AM EDT - 4 weeks ago

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

Apr 29, 2026, 7:50 AM EDT - 4 weeks ago

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

Apr 29, 2026, 7:47 AM EDT - 4 weeks ago

AbbVie Reports First-Quarter 2026 Financial Results

Apr 28, 2026, 8:00 AM EDT - 4 weeks ago

AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata

Apr 28, 2026, 7:00 AM EDT - 4 weeks ago

EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie

Apr 27, 2026, 8:05 AM EDT - 5 weeks ago

AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

Apr 23, 2026, 4:19 PM EDT - 5 weeks ago

US FDA declines to approve AbbVie's wrinkle treatment

Apr 23, 2026, 4:05 PM EDT - 5 weeks ago

AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.

Apr 22, 2026, 12:59 PM EDT - 5 weeks ago

AbbVie to build $1.4 billion manufacturing campus in North Carolina

Apr 22, 2026, 12:02 PM EDT - 5 weeks ago

AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus

Apr 20, 2026, 2:30 AM EDT - 6 weeks ago

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

Apr 14, 2026, 8:50 AM EDT - 6 weeks ago

Erin Lichy Gets Real About Her Natrelle® Breast Augmentation

Apr 13, 2026, 2:24 AM EDT - 7 weeks ago

Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain

Apr 12, 2026, 7:15 AM EDT - 7 weeks ago

AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026

Apr 8, 2026, 1:38 PM EDT - 7 weeks ago

AbbVie files lawsuit to address 'outdated' drug discount eligibility program

Apr 8, 2026, 8:00 AM EDT - 7 weeks ago

BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year

Apr 7, 2026, 9:53 AM EDT - 7 weeks ago

The price Americans pay for medicine has gotten horribly out of control. Here's how to fix it.

Apr 7, 2026, 9:00 AM EDT - 7 weeks ago

Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin

Apr 3, 2026, 11:08 AM EDT - 2 months ago

Swiss industry body says US tariffs on pharmaceuticals will harm patients

AMGN AZN BMY MRK NVO

Apr 2, 2026, 5:34 PM EDT - 2 months ago

Trump Administration Unveils Up to 100% Tariff on Branded Drugs

AZN NVO AMGN BMY MRK

Apr 2, 2026, 5:33 PM EDT - 2 months ago

Trump threatens 100% tariff on US drug makers that don't strike deals to lower prices

AMGN AZN BMY MRK NVO

Apr 2, 2026, 3:29 PM EDT - 2 months ago

Drugmakers face 100% tariff unless they cut prices or produce drugs in US

AZN NVO AMGN BMY MRK

Apr 2, 2026, 2:59 PM EDT - 2 months ago

Global pharma companies that have publicly announced Trump drug pricing agreements

AMGN AZN BMY MRK

Mar 31, 2026, 8:05 AM EDT - 2 months ago

Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting®

Mar 31, 2026, 8:00 AM EDT - 2 months ago

AbbVie to Host First-Quarter 2026 Earnings Conference Call

Mar 27, 2026, 10:00 AM EDT - 2 months ago

AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting

Mar 24, 2026, 8:00 AM EDT - 2 months ago

AbbVie Named Official Pharmaceutical Partner of Major League Baseball

Mar 23, 2026, 8:00 AM EDT - 2 months ago

AbbVie Proxy statement: Proxy filing

Mar 23, 2026, 8:00 AM EDT - 2 months ago

AbbVie Proxy statement: Proxy filing

Mar 20, 2026, 12:11 PM EDT - 2 months ago

US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings

AMRX NVS OGN

Mar 19, 2026, 9:26 AM EDT - 2 months ago

Buy Or Fear AbbVie Stock At $210?

Mar 19, 2026, 3:00 AM EDT - 2 months ago

Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions

Mar 18, 2026, 2:23 PM EDT - 2 months ago

TrumpRx lists many medicines at prices higher than paid in UK

AMGN AZN BMY GILD GSK JNJ LLY

Mar 17, 2026, 2:32 PM EDT - 2 months ago

Big drugmakers must face US overcharge claims on medications for low-income patients

AZN NVS SNY

Mar 13, 2026, 9:00 AM EDT - 2 months ago

New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row

Mar 10, 2026, 11:20 AM EDT - 2 months ago

AbbVie Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 8:00 AM EDT - 3 months ago

AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

Mar 9, 2026, 8:00 AM EDT - 3 months ago

AbbVie Proxy statement: Proxy Filing

Mar 3, 2026, 11:10 AM EST - 3 months ago

AbbVie Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 8:00 AM EST - 3 months ago

AbbVie to Present at the Leerink Partners Global Healthcare Conference

Mar 2, 2026, 8:30 AM EST - 3 months ago

AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease

Feb 24, 2026, 8:00 AM EST - 3 months ago

AbbVie to Present at the TD Cowen 46th Annual Health Care Conference

Feb 23, 2026, 12:03 PM EST - 3 months ago

AbbVie to invest $380 million to expand US manufacturing in Illinois

clan Jun. 1 at 12:15 PM

0 · Reply

55X_ROI_Q1_2026 Jun. 1 at 5:37 AM

$SLS $ABBV

1 · Reply

maikl_211 Jun. 1 at 4:29 AM

$PLTR $COST $NFLX $BAC $ABBV

0 · Reply

Loudermilk64 Jun. 1 at 4:23 AM

$ABBV dead money.

0 · Reply

55X_ROI_Q1_2026 Jun. 1 at 3:26 AM

0 · Reply

55X_ROI_Q1_2026 Jun. 1 at 3:14 AM

0 · Reply

TruthBroker2 May. 31 at 3:22 PM

$ABBV $ISRG $PLSE $SMMT.

0 · Reply

55X_ROI_Q1_2026 May. 31 at 3:32 AM

0 · Reply

amessagefromtheodd May. 30 at 11:24 AM

1 · Reply

clan May. 29 at 9:22 PM

$MNKD ⚠️ FDA APPROVAL ⚠️ Inhalable mealtime insulin for pediatrics! Wow! 😲 Good for kids, mankind, and Mannkind ! ... and Cipla too ! $CIPLA.NSE 🇮🇳 $GSK $ABBV

0 · Reply

55X_ROI_Q1_2026 May. 29 at 5:25 PM

$SLS $ABBV - this Manipulated $9 stock / $1.7B MCAP equity - is a $90 Stock / $17B and Climbing the Instant Gps Phase 3 Results are Announced - they are Coming - Will Be ANY DAY NOW - They Are Inevitable. - Be HoDLING - when we get the PR Phase 3 Results are worth every nickel of $40B to BP Short Market Manipulation offering the Investment Opportunity of a Lifetime. $ABVX was a $5 Stock - Bumping around $5 - $8 and then had Risen to $10 in the days Right before Its P3 was Announced. T1 TRADING HALT +600% GAP UP to $60 and it Kept Climbing to a high of $148 as the market digested BO Value.

0 · Reply

55X_ROI_Q1_2026 May. 29 at 4:33 PM

$SLS $ABBV While we are Seeing Miraculous All Pooled Survival in the SLS Phase 3 REGAL Trial Patients - Aza+VEN - BAT - Best Available Treatment for the Control Arm patients Recently Failed 3 Large Phase 3 Trials. it is not complicated. This $9.40 Stock is about to be a $94 Stock and it'll still have a double in it for VANGAURD and BLACK ROCK

0 · Reply

55X_ROI_Q1_2026 May. 29 at 4:27 PM

$SLS $ABBV $93 Stock $17B Currently Trading for a Manipulated $9.30 / $1.7B - do your due diligence. Gps Phase 3 Results, 5 + years in the making are Coming - they are Inevitable and worth every nickel of $40B to Big Pharma. The Share Price will continue climbing until we get the 80th EVENT PR and Then its Full on Launch Time.

0 · Reply

55X_ROI_Q1_2026 May. 29 at 4:02 PM

$SLS VIALE-M the $ABBV Phase 3 for AML First Remission Maintenance (CR1) - Failed - 7 Different Dosing Regimes - were Tried, High Intensity Low Intensity, IV Sub Q and all ORAL ... ALL too Toxic. - Results are Public https://clinicaltrials.gov/study/NCT04102020?term=viale-M&viewType=Card&rank=1&tab=study#publications the SAP went through 7 iterations ABBV $RHHBY $BMY -- these Big Pharma - who Own Aza Ven, and Paid for the P3 trials - KNOW RIGHT NOW - it is GPS Doing what its done in ALL PRIOR Trials - Prevent Relapse and Extend Survival.

0 · Reply

55X_ROI_Q1_2026 May. 29 at 3:47 PM

$SLS $ABBV While we are seeing, and awaiting Miraculous Survival Results - for these Second Remission CR2/3 patients who harbour residual disease and 'high risk of relapse" - Aza+VEN, BAT for CONTROL ARM Patients, Recently Failed 3 Large Phase 3 Trials conducted by $ABBV VIALE-M - AML First Remission CR1 Maintenance Phase 3 Failed VIALE-T - AML Post Transplant Maintenance Phase 3 Failed VERONA - High Risk MDS/AML precursor Phase 3 Failed - even in the VIALE-A trial - where real world results have not been replicated, --- 23% of the Patients Taking Aza+VEN DIED from Taking Aza+VEN ... and 88% had Serious Side Effects. - Gps has proven effective in all prior trials, including 2 Phase 2 Trials for AML remission Maintenance, with Gps Specifice Immune Response correlated to Increased Survival.... It is Not complicated

0 · Reply

Loudermilk64 May. 29 at 2:20 PM

$ABBV who bought the daily dip?

0 · Reply

focafoca99 May. 29 at 12:15 PM

$ABBV earned European Commission approval for an expanded VENCLYXTO label covering new first‑line CLL combinations. https://www.rapidticker.com/news/abbv-abbvie-announces-european-commission-authorization-80a9

0 · Reply

focafoca99 May. 29 at 12:10 PM

$ABBV received European Commission approval for an expanded VENCLYXTO label covering new first‑line CLL combos. https://www.rapidticker.com/news/abbv-abbvie-announces-european-commission-authorization-b3db

0 · Reply

55X_ROI_Q1_2026 May. 29 at 12:50 AM

$SLS $GILD Reminder(s) SLS-009 Phase 2 B AML-MR Data ALREADY Published at ASH is Better than P1B AML-MR Data that Got Bought for $4.9B.... Just the "secondary Asset" is Right Now Worth $27 Per Share. - While we are seeing and waiting for Near Miraculous Survival in All Pooled Patients ---- Aza+VEN BAT Best Available Treatment for Control Patients in the REGAL Trial - Recently FAILED 3 Large Phase 3 Trials conducted by $ABBV - Including Failing the VIALE-T Post Transplant Maintenance P3 and Failing the VIALE-M - First Remission CR1 Maintenance P3 Trial. it is also Failing the SLS Phase 3 CR2 Maintenance P3 Trial ---

0 · Reply

semiguy May. 28 at 11:54 PM

$FRVO $NNE $ABBV $TJX told you last week - Magnachip to Showcase MV MOSFET Portfolio for AI Servers and Data Centers Alongside Its Broader Power Semiconductor Portfolio at PCIM Europe 2026 SYMBOL(MX) Magnachip a small cap power solutions semiconductor company based in South Korea. • MKT Cap of $230 million. • Revenue of $180 million. • 8 inch foundry worth approximately 200 million – 36K wafers a month • Cash of $50 million, trading at $5.70 a share. ( as of last Friday) • Won’t be at this price for long. Magnachip to Showcase MV MOSFET Portfolio for AI Servers and Data Centers Alongside Its Broader Power Semiconductor Portfolio at PCIM Europe https://www.businesswire.com/news/home/20260526332549/en/Magnachip-to-Showcase-MV-MOSFET-Portfolio-for-AI-Servers-and-Data-Centers-Alongside-Its-Broader-Power-Semiconductor-Portfolio-at-PCIM-Europe-2026

0 · Reply

Mike22332233 May. 28 at 8:17 PM

$SLS UPDATED ... Timeline/Price Prediction: ... SLS will jump to $18-$22 at 80th event ... and then RUN UP TO $55-$60 on GROUNDBREAKING readout results a month later !!! ... from there, it will drift up to the $75-$80 area over the next month ... and soon after, the opening BO Offer will be place at about $140-$160 ... After, a 3 way Bidding War --between $MRK, $PFE, and $ABBV -- the FINAL BO PRICE will be reached at $222 in Q4 of 2026 !!! .. From here, SLS could return 1,650%-2,650% ... the single best asymmetrical investment I've seen in my 40+ years of investing & largest holding in $1.4 Mil portfolio !! .. ALSO, tomorrow I expect the twice delayed TO for $LSTA at $5.00 plus a CVR for another future possible $1.00, to move forward, and from current $3.14 price, to give me a +59% return ... If you agree, LIKE & FOLLOW me 👉 @Mike22332233 as I post my Special Situation Stocks that have potential for FAST & HUGE profits ... which I always plow back into more $SLS !!!

2 · Reply

Petersen73 May. 28 at 7:58 PM

$ABBV $CING $SCHW $SLS

0 · Reply

Market Cap	384.67B
Revenue (ttm)	61.16B
Net Income (ttm)	4.23B
EPS (ttm)	N/A
PE Ratio	21.46
Forward PE	15.29
Profit Margin	6.91%
Debt to Equity Ratio	-11.02

Volume	7,620,800
Avg Vol	6,725,842
Day's Range	N/A - N/A
Shares Out	1.77B
Stochastic %K	81%
Beta	0.32
Analysts	Strong Sell
Price Target	$250.90